Related Experiment Videos
[Febrile reaction to D-penicillamine]
La Semaine Des Hopitaux : Organe Fonde Par L'Association D'Enseignement Medical Des Hopitaux De Paris
|March 8, 1984
Summary
D-penicillamine can cause a uniform febrile reaction in rheumatoid arthritis patients. Progressive reintroduction may be successful in Wilson disease cases, though the mechanism remains unknown.
Area of Science:
- Rheumatology
- Pharmacology
- Hepatology
Background:
- Rheumatoid arthritis (RA) is a chronic autoimmune disease.
- D-penicillamine is a chelating agent used in treating RA and Wilson disease.
- Febrile reactions are a known potential adverse effect of D-penicillamine.
Observation:
- Two patients with rheumatoid arthritis experienced a febrile reaction to D-penicillamine.
- The clinical presentation of the febrile reaction was notably uniform across both patients.
Findings:
- The exact physiopathological mechanism underlying D-penicillamine-induced fever remains undetermined.
- Despite the febrile reaction, successful reintroduction of D-penicillamine was achieved in a patient with Wilson disease through progressive administration.
Implications:
- Understanding the uniform presentation of febrile reactions aids in clinical recognition.
- Further research into the mechanism of D-penicillamine fever is warranted.
- Careful, progressive reintroduction of D-penicillamine may be a viable strategy in specific patient populations, such as those with Wilson disease.